{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:03:29Z","timestamp":1790298209202,"version":"4.1.0"},"reference-count":162,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009670","name":"National Alliance for Research on Schizophrenia and Depression","doi-asserted-by":"publisher","award":["83561"],"award-info":[{"award-number":["83561"]}],"id":[{"id":"10.13039\/100009670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009670","name":"National Alliance for Research on Schizophrenia and Depression","doi-asserted-by":"publisher","award":["27802"],"award-info":[{"award-number":["27802"]}],"id":[{"id":"10.13039\/100009670","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.biopsych.2024.01.019","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:42:58Z","timestamp":1706834578000},"page":"352-364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Imaging the Vesicular Acetylcholine Transporter in Schizophrenia: A Positron Emission Tomography Study Using [18F]-VAT"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0396-3596","authenticated-orcid":false,"given":"Jodi J.","family":"Weinstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Moeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared X.","family":"Van Snellenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Wengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Slifstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa","family":"Abi-Dargham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2024.01.019_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2004.09.009","article-title":"Longitudinal studies of cognition and functional outcome in schizophrenia: Implications for MATRICS","volume":"72","author":"Green","year":"2004","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2024.01.019_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders","article-title":"Schizophrenia spectrum and other psychotic disorders","year":"2013"},{"key":"10.1016\/j.biopsych.2024.01.019_bib3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2024.01.019_bib4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2024.01.019_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archpsyc.1988.01800250087012","article-title":"Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs","volume":"45","author":"Farde","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-3223(93)90288-O","article-title":"Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients","volume":"33","author":"Nordstr\u00f6m","year":"1993","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib7","doi-asserted-by":"crossref","first-page":"PL 207","DOI":"10.1016\/S0024-3205(97)00026-X","article-title":"Clozapine occupies high levels of dopamine D2 receptors","volume":"60","author":"Seeman","year":"1997","journal-title":"Life Sci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib9","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2004.01.027","article-title":"A\u00a0meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: Opening a closed book","volume":"55","author":"Mishara","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib11","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41380-019-0502-5","article-title":"The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis","volume":"26","author":"McCutcheon","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1126\/science.9693","article-title":"Dopamine receptors and average clinical doses","volume":"194","author":"Meltzer","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2024.01.019_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pneurobio.2016.07.004","article-title":"New drug developments in psychosis: Challenges, opportunities and strategies","volume":"152","author":"Keshavan","year":"2017","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.biopsych.2024.01.019_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/npp.2011.199","article-title":"Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia","volume":"37","author":"Jones","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev-med-092112-142937","article-title":"\u03b17-Nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia","volume":"65","author":"Freedman","year":"2014","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.biopsych.2024.01.019_bib17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40263-015-0260-0","article-title":"The therapeutic potential of alpha7 nicotinic acetylcholine receptor (\u03b17 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia","volume":"29","author":"Beinat","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopsych.2024.01.019_bib18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.biopsych.2024.01.019_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113201","article-title":"Targeting muscarinic receptors to treat schizophrenia","volume":"405","author":"Foster","year":"2021","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2024.01.019_bib20","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14316","article-title":"Antipsychotic efficacy of KarXT (xanomeline-Trospium): Post hoc analysis of Positive and Negative Syndrome Scale categorical response rates, time course of response, and symptom domains of response in a phase 2 study","volume":"83","author":"Weiden","year":"2022","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib21","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","article-title":"Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia","volume":"179","author":"Paul","year":"2022","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib22","author":"Paul"},{"key":"10.1016\/j.biopsych.2024.01.019_bib23","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/archpsyc.63.6.630","article-title":"Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia","volume":"63","author":"Olincy","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib24","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1176\/appi.ajp.2008.07071135","article-title":"Initial phase 2 trial of a nicotinic agonist in schizophrenia","volume":"165","author":"Freedman","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/npp.2017.182","article-title":"Pharmacokinetic limitations on effects of an alpha7-nicotinic receptor agonist in schizophrenia: Randomized trial with an extended-release formulation","volume":"43","author":"Kem","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib26","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41386-020-0628-9","article-title":"Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients","volume":"45","author":"Kantrowitz","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0304-3940(00)01144-7","article-title":"Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson\u2019s syndrome","volume":"287","author":"Durany","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.biopsych.2024.01.019_bib28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0893-133X(00)00121-4","article-title":"Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia","volume":"23","author":"Breese","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1017\/S1461145712000028","article-title":"Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia","volume":"16","author":"Gibbons","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib30","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1503\/jpn.170202","article-title":"Low levels of muscarinic M1 receptor-positive neurons in cortical layers III and V in Brodmann areas 9 and 17 from individuals with schizophrenia","volume":"43","author":"Scarr","year":"2018","journal-title":"J\u00a0Psychiatry Neurosci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/mp.2016.195","article-title":"Changed gene expression in subjects with schizophrenia and low cortical muscarinic M1 receptors predicts disrupted upstream pathways interacting with that receptor","volume":"23","author":"Scarr","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib32","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1176\/appi.ajp.2011.11020189","article-title":"Lower \u00df2\u2217-nicotinic acetylcholine receptor availability in smokers with schizophrenia","volume":"169","author":"D\u2019Souza","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.biopsych.2013.11.001","article-title":"In\u00a0vivo evidence for beta2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia","volume":"76","author":"Esterlis","year":"2014","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib34","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/ijnp\/pyy021","article-title":"Brain PET imaging of \u03b17-nAChR with [18F]ASEM: Reproducibility, occupancy, receptor density, and changes in schizophrenia","volume":"21","author":"Wong","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2024.01.019_bib35","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.1093\/schbul\/sby017.679","article-title":"F148. A pilot study of [11C] (R)-MEQAA PET brain imaging analysis of alpha 7 nicotinic acetylcholine receptors availability in schizophrenia","volume":"44","author":"Wakuda","year":"2018","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2024.01.019_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s002130000679","article-title":"Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study","volume":"156","author":"Lavalaye","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0893-133X(99)00162-1","article-title":"In\u00a0vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia","volume":"23","author":"Raedler","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.160.1.118","article-title":"In\u00a0vivo determination of muscarinic acetylcholine receptor availability in schizophrenia","volume":"160","author":"Raedler","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib39","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/sj.npp.1300210","article-title":"Central muscarinic acetylcholine receptor availability in patients treated with clozapine","volume":"28","author":"Raedler","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0920-9964(91)90006-D","article-title":"Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms","volume":"4","author":"Tandon","year":"1991","journal-title":"Schizophr Res"},{"issue":"37","key":"10.1016\/j.biopsych.2024.01.019_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/S0007125000293586","article-title":"Cholinergic aspects of schizophrenia","volume":"Suppl","author":"Tandon","year":"1999","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib42","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0013-4694(60)90010-9","article-title":"Effect of antichlolinergic compounds on post convulsive electroencephalogram and behavior of psychiatric patients","volume":"12","author":"Fink","year":"1960","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib43","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/brain\/115.6.1681","article-title":"Cholinergic \u2018blockade\u2019 as a model of the cognitive deficits in Alzheimer\u2019s disease","volume":"115","author":"Christensen","year":"1992","journal-title":"Brain"},{"key":"10.1016\/j.biopsych.2024.01.019_bib44","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.biopsych.2024.01.019_bib45","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s11033-021-06264-6","article-title":"Molecular mechanisms involved in the prevention and reversal of ketamine-induced schizophrenia-like behavior by rutin: The role of glutamic acid decarboxylase isoform-67, cholinergic, Nox-2-oxidative stress pathways in mice","volume":"48","author":"Oshodi","year":"2021","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.biopsych.2024.01.019_bib46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0891-0618(01)00101-6","article-title":"Cholinergic systems and schizophrenia: Primary pathology or epiphenomena?","volume":"22","author":"Hyde","year":"2001","journal-title":"J\u00a0Chem Neuroanat"},{"key":"10.1016\/j.biopsych.2024.01.019_bib47","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0074-7742(06)78008-4","article-title":"Schizophrenia and the alpha7 nicotinic acetylcholine receptor","volume":"78","author":"Martin","year":"2007","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib48","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.neuropharm.2010.12.001","article-title":"Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments","volume":"62","author":"Sarter","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib49","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.conb.2014.06.004","article-title":"Neuromodulation by acetylcholine: Examples from schizophrenia and depression","volume":"29","author":"Higley","year":"2014","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib50","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.neuron.2007.09.001","article-title":"The neurotransmitter cycle and quantal size","volume":"55","author":"Edwards","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2024.01.019_bib51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/0269881114566743","article-title":"Schizophrenia in the 21st century: New insights and translation into improved therapies","volume":"29","author":"Pratt","year":"2015","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib52","doi-asserted-by":"crossref","first-page":"27229","DOI":"10.1074\/jbc.271.44.27229","article-title":"Active transport of acetylcholine by the human vesicular acetylcholine transporter","volume":"271","author":"Varoqui","year":"1996","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.biopsych.2024.01.019_bib53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1042\/BJ20121662","article-title":"Regulation of cholinergic activity by the vesicular acetylcholine transporter","volume":"450","author":"Prado","year":"2013","journal-title":"Biochem J"},{"key":"10.1016\/j.biopsych.2024.01.019_bib54","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1054-3589(08)60745-0","article-title":"Imaging of monoaminergic and cholinergic vesicular transporters in the brain","volume":"42","author":"Frey","year":"1998","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1601-183X.2008.00439.x","article-title":"Reduced expression of the vesicular acetylcholine transporter causes learning deficits in mice","volume":"8","author":"de Castro","year":"2009","journal-title":"Genes Brain Behav"},{"key":"10.1016\/j.biopsych.2024.01.019_bib56","doi-asserted-by":"crossref","first-page":"17651","DOI":"10.1073\/pnas.1215381109","article-title":"Elimination of the vesicular acetylcholine transporter in the forebrain causes hyperactivity and deficits in spatial memory and long-term potentiation","volume":"109","author":"Martyn","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.biopsych.2024.01.019_bib57","first-page":"405","article-title":"In\u00a0vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM","volume":"35","author":"Kuhl","year":"1994","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.biopsych.2024.01.019_bib58","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neuroimage.2007.11.028","article-title":"In\u00a0vivo SPECT imaging of vesicular acetylcholine transporter using [(123)I]-IBVM in early Alzheimer\u2019s disease","volume":"40","author":"Maz\u00e8re","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.biopsych.2024.01.019_bib59","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2967\/jnumed.116.176180","article-title":"123I-Iodobenzovesamicol SPECT imaging of cholinergic systems in dementia with Lewy bodies","volume":"58","author":"Maz\u00e8re","year":"2017","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.biopsych.2024.01.019_bib60","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/mp.2017.183","article-title":"Quantification of brain cholinergic denervation in Alzheimer\u2019s disease using PET imaging with [18F]-FEOBV","volume":"22","author":"Aghourian","year":"2017","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib61","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41380-018-0130-5","article-title":"Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBV","volume":"24","author":"Nejad-Davarani","year":"2019","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.sleep.2018.12.020","article-title":"Brain cholinergic alterations in idiopathic REM sleep behaviour disorder: A PET imaging study with 18F-FEOBV","volume":"58","author":"Bedard","year":"2019","journal-title":"Sleep Med"},{"key":"10.1016\/j.biopsych.2024.01.019_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2022.102992","article-title":"Reduced cortical cholinergic innervation measured using [18F]-FEOBV PET imaging correlates with cognitive decline in mild cognitive impairment","volume":"34","author":"Xia","year":"2022","journal-title":"NeuroImage Clin"},{"key":"10.1016\/j.biopsych.2024.01.019_bib64","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1096\/fj.00-0204rev","article-title":"In\u00a0vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter","volume":"14","author":"Efange","year":"2000","journal-title":"FASEB J"},{"key":"10.1016\/j.biopsych.2024.01.019_bib65","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.apradiso.2015.09.010","article-title":"Automated production of [18F]VAT suitable for clinical PET study of vesicular acetylcholine transporter","volume":"107","author":"Yue","year":"2016","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.biopsych.2024.01.019_bib66","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1021\/jm9017916","article-title":"Synthesis and in\u00a0vitro biological evaluation of carbonyl group-containing inhibitors of vesicular acetylcholine transporter","volume":"53","author":"Efange","year":"2010","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.biopsych.2024.01.019_bib67","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.brainresbull.2005.09.018","article-title":"Dopamine release in human neocortical slices: Characterization of inhibitory autoreceptors and of nicotinic acetylcholine receptor-evoked release","volume":"68","author":"L\u00f6ffler","year":"2006","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.biopsych.2024.01.019_bib68","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.neuroscience.2006.03.055","article-title":"Reduced expression and capacity of the striatal high-affinity choline transporter in hyperdopaminergic mice","volume":"141","author":"Parikh","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2024.01.019_bib69","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/sj.npp.1301352","article-title":"Toward a neuro-cognitive animal model of the cognitive symptoms of\u00a0schizophrenia: Disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing, rats","volume":"32","author":"Kozak","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib70","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1460-9568.2009.06613.x","article-title":"alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in\u00a0vitro and in\u00a0vivo in the rat prefrontal cortex","volume":"29","author":"Livingstone","year":"2009","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib71","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00213-013-3082-0","article-title":"Ventral tegmental area \u03b16\u03b22 nicotinic acetylcholine receptors modulate phasic dopamine release in the nucleus accumbens core","volume":"229","author":"Wickham","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib72","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.bbr.2015.05.036","article-title":"Muscarinic, but not nicotinic, acetylcholine receptor blockade in the ventral tegmental area attenuates cue-induced sucrose-seeking","volume":"291","author":"Addy","year":"2015","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2024.01.019_bib73","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.neuron.2016.08.017","article-title":"Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release","volume":"91","author":"Foster","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2024.01.019_bib74","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s13311-019-00830-4","article-title":"DREADD activation of pedunculopontine cholinergic neurons reverses motor deficits and restores striatal dopamine signaling in parkinsonian rats","volume":"17","author":"Sharma","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.biopsych.2024.01.019_bib75","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1523\/JNEUROSCI.0755-20.2021","article-title":"Coordinated postnatal maturation of striatal cholinergic interneurons and dopamine release dynamics in mice","volume":"41","author":"McGuirt","year":"2021","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.tins.2006.01.003","article-title":"Meaningful silences: How dopamine listens to the ACh pause","volume":"29","author":"Cragg","year":"2006","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib77","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.bcp.2009.06.004","article-title":"Nicotinic acetylcholine receptors and the ascending dopamine pathways","volume":"78","author":"Livingstone","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib78","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.neuron.2013.12.027","article-title":"Dopamine neurons control striatal cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling","volume":"81","author":"Chuhma","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2024.01.019_bib79","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.957","article-title":"Central cholinergic system mediates working memory deficit induced by anesthesia\/surgery in adult mice","volume":"8","author":"Zhang","year":"2018","journal-title":"Brain Behav"},{"key":"10.1016\/j.biopsych.2024.01.019_bib80","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1523\/JNEUROSCI.0364-17.2017","article-title":"Nicotinic \u03b16\u03b22 cholinergic receptor influences on dorsolateral prefrontal cortical neuronal firing during a working memory task","volume":"37","author":"Sun","year":"2017","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib81","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00406-011-0267-6","article-title":"Cholinergic blockade under working memory demands encountered by increased rehearsal strategies: Evidence from fMRI in healthy subjects","volume":"262","author":"Voss","year":"2012","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib82","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1037\/a0026198","article-title":"Dopaminergic and cholinergic modulations of visual-spatial attention and working memory: Insights from molecular genetic research and implications for adult cognitive development","volume":"48","author":"St\u00f6rmer","year":"2012","journal-title":"Dev Psychol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib83","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1523\/JNEUROSCI.4673-11.2012","article-title":"Prior pathology in the basal forebrain cholinergic system predisposes to inflammation-induced working memory deficits: Reconciling inflammatory and cholinergic hypotheses of delirium","volume":"32","author":"Field","year":"2012","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib84","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1152\/jn.00148.2011","article-title":"Cholinergic modulation of working memory activity in primate prefrontal cortex","volume":"106","author":"Zhou","year":"2011","journal-title":"J\u00a0Neurophysiol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib85","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euroneuro.2010.10.011","article-title":"Evidence for the modality independence of the genetic epistasis between the dopaminergic and cholinergic system on working memory capacity","volume":"21","author":"Markett","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib86","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.brainresbull.2009.01.013","article-title":"Cholinergic modulation of visual working memory during aging: A parametric PET study","volume":"79","author":"Ricciardi","year":"2009","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.biopsych.2024.01.019_bib87","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1523\/JNEUROSCI.1885-08.2008","article-title":"Functional convergence of dopaminergic and cholinergic input is critical for hippocampus-dependent working memory","volume":"28","author":"Wisman","year":"2008","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib88","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1162\/jocn.2008.20092","article-title":"Cholinergic enhancement eliminates modulation of neural activity by task difficulty in the prefrontal cortex during working memory","volume":"20","author":"Furey","year":"2008","journal-title":"J\u00a0Cogn Neurosci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib89","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1101\/lm.70904","article-title":"Cholinergic modulation of visual attention and working memory: Dissociable effects of basal forebrain 192-IgG-saporin lesions and intraprefrontal infusions of scopolamine","volume":"11","author":"Chudasama","year":"2004","journal-title":"Learn Mem"},{"key":"10.1016\/j.biopsych.2024.01.019_bib90","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00008877-200203000-00008","article-title":"Modulation of working memory and of long- but not short-term memory by cholinergic mechanisms in the basolateral amygdala","volume":"13","author":"Barros","year":"2002","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib91","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0361-9230(99)00219-1","article-title":"Cholinergic enhancement improves performance on working memory by modulating the functional activity in distinct brain regions: A positron emission tomography regional cerebral blood flow study in healthy humans","volume":"51","author":"Furey","year":"2000","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.biopsych.2024.01.019_bib92","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0149-7634(96)00065-6","article-title":"The role of the dorsal raphe-serotonergic system and cholinergic receptors in the modulation of working memory","volume":"22","author":"Ruotsalainen","year":"1998","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2024.01.019_bib93","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/nlme.1995.0005","article-title":"Distinct profile of working memory errors following acute or chronic disruption of the cholinergic septohippocampal pathway","volume":"64","author":"Stackman","year":"1995","journal-title":"Neurobiol Learn Mem"},{"key":"10.1016\/j.biopsych.2024.01.019_bib94","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0006-8993(94)90964-4","article-title":"Working memory performance and cholinergic effects in the ventral tegmental area and substantia nigra","volume":"657","author":"Levin","year":"1994","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2024.01.019_bib95","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1037\/0735-7044.104.6.849","article-title":"Cholinergic and GABAergic modulation of medial septal area: Effect on working memory","volume":"104","author":"Givens","year":"1990","journal-title":"Behav Neurosci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib96","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0166-4328(89)80082-8","article-title":"In\u00a0vivo modulation of septo-hippocampal cholinergic activity in mice: Relationships with spatial reference and working memory performance","volume":"32","author":"Galey","year":"1989","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2024.01.019_bib97","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0006-8993(87)91322-9","article-title":"AF64A (ethylcholine aziridinium ion), a cholinergic neurotoxin, selectively impairs working memory in a multiple component T-maze task","volume":"414","author":"Chrobak","year":"1987","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2024.01.019_bib98","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1037\/0735-7044.99.6.1049","article-title":"Central cholinergic involvement in working memory: Effects of scopolamine on continuous nonmatching and discrimination performance in the rat","volume":"99","author":"Spencer","year":"1985","journal-title":"Behav Neurosci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib99","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.1073\/pnas.93.17.9235","article-title":"Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects","volume":"93","author":"Laruelle","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.biopsych.2024.01.019_bib100","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1073\/pnas.94.6.2569","article-title":"Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method","volume":"94","author":"Breier","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.biopsych.2024.01.019_bib101","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0920-9964(96)00102-8","article-title":"Presynaptic dopaminergic function\u00a0in the striatum of schizophrenic patients","volume":"23","author":"Dao-Castellana","year":"1997","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2024.01.019_bib102","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/ajp.155.6.761","article-title":"Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort","volume":"155","author":"Abi-Dargham","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib103","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0006-3223(99)00067-0","article-title":"Increased dopamine transmission in schizophrenia: Relationship to illness phases","volume":"46","author":"Laruelle","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib104","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0006-3223(99)00109-2","article-title":"Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET","volume":"46","author":"Lindstr\u00f6m","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0925-4927(00)00064-0","article-title":"6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography","volume":"100","author":"Elkashef","year":"2000","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2024.01.019_bib106","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/archpsyc.61.2.134","article-title":"Presynaptic dopaminergic dysfunction in schizophrenia: A positron emission tomographic [18F]fluorodopa study","volume":"61","author":"McGowan","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib107","doi-asserted-by":"crossref","first-page":"8080","DOI":"10.1523\/JNEUROSCI.0805-07.2007","article-title":"Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: An [18F]fluorodopa\/positron emission tomography study","volume":"27","author":"Kumakura","year":"2007","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib108","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.biopsych.2008.12.007","article-title":"Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects","volume":"65","author":"Abi-Dargham","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib109","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.biopsych.2010.05.027","article-title":"Striatal and extrastriatal dopamine D2\/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography","volume":"68","author":"Kegeles","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.schres.2010.03.043","article-title":"18F-fallypride binding potential in patients with schizophrenia compared to healthy controls","volume":"122","author":"Lehrer","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2024.01.019_bib111","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/syn.20734","article-title":"Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride","volume":"64","author":"Slifstein","year":"2010","journal-title":"Synapse"},{"key":"10.1016\/j.biopsych.2024.01.019_bib112","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archgenpsychiatry.2010.10","article-title":"Increased synaptic dopamine function in associative regions of the striatum in schizophrenia","volume":"67","author":"Kegeles","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib113","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.biopsych.2011.10.009","article-title":"Increased stress-induced dopamine release in psychosis","volume":"71","author":"Mizrahi","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib114","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/schbul\/sbr180","article-title":"Striatal presynaptic dopamine in schizophrenia, part II: Meta-analysis of [(18)F\/(11)C]-DOPA PET studies","volume":"39","author":"Fusar-Poli","year":"2013","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2024.01.019_bib115","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/mp.2012.109","article-title":"Striatal dopamine release in schizophrenia comorbid with substance dependence","volume":"18","author":"Thompson","year":"2013","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib116","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1192\/bjp.bp.113.132308","article-title":"Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: Systematic review and meta-analysis of imaging studies","volume":"204","author":"Kambeitz","year":"2014","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib117","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.biopsych.2017.11.032","article-title":"Amphetamine-induced striatal dopamine release measured with an agonist radiotracer in schizophrenia","volume":"83","author":"Frankle","year":"2018","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib118","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.biopsych.2022.05.009","article-title":"Prefrontal and striatal dopamine release are inversely correlated in schizophrenia","volume":"92","author":"Frankle","year":"2022","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib119","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1176\/jnp.6.4.348","article-title":"Working memory dysfunction in schizophrenia","volume":"6","author":"Goldman-Rakic","year":"1994","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib120","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0006-3223(99)00130-4","article-title":"The physiological approach: Functional architecture of working memory and disordered cognition in schizophrenia","volume":"46","author":"Goldman-Rakic","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib121","first-page":"707","article-title":"The cortical dopamine system: Role in memory and cognition","volume":"42","author":"Goldman-Rakic","year":"1998","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib122","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF01499321","article-title":"The MacArthur Treatment Competence Study. I: Mental illness and competence to consent to treatment","volume":"19","author":"Appelbaum","year":"1995","journal-title":"Law Hum Behav"},{"key":"10.1016\/j.biopsych.2024.01.019_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2005.08.007","article-title":"Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial","volume":"80","author":"Stroup","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2024.01.019_bib124","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1037\/neu0000011","article-title":"Neuroimaging predictors of cognitive performance across a standardized neurocognitive battery","volume":"28","author":"Roalf","year":"2014","journal-title":"Neuropsychology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib125","series-title":"Structured Clinical Interview for DSM-5, research version","author":"First","year":"2015"},{"key":"10.1016\/j.biopsych.2024.01.019_bib126","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0028-3932(71)90067-4","article-title":"The assessment and analysis of handedness: The Edinburgh inventory","volume":"9","author":"Oldfield","year":"1971","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.biopsych.2024.01.019_bib127","author":"Hollingshead"},{"key":"10.1016\/j.biopsych.2024.01.019_bib128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2024.01.019_bib129","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/jlcr.4059","article-title":"An improved synthesis of [18 F]VAT and its precursor","volume":"66","author":"Hu","year":"2023","journal-title":"J\u00a0Labelled Comp Radiopharm"},{"key":"10.1016\/j.biopsych.2024.01.019_bib130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.neuroimage.2016.12.010","article-title":"A\u00a0multi-centre evaluation of eleven clinically feasible brain PET\/MRI attenuation correction techniques using a large cohort of patients","volume":"147","author":"Ladefoged","year":"2017","journal-title":"Neuroimage"},{"key":"10.1016\/j.biopsych.2024.01.019_bib131","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/00004647-200109000-00002","article-title":"Imaging human mesolimbic dopamine transmission with PET: I. Accuracy and precision of D(2) parameter measurements in the ventral striatum","volume":"21","author":"Mawlawi","year":"2001","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2024.01.019_bib132","first-page":"2001","article-title":"MR anatomy of the substantia innominata and findings in Alzheimer disease: A preliminary report","volume":"16","author":"Sasaki","year":"1995","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib133","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/hbm.21111","article-title":"The cholinergic system in mild cognitive impairment and Alzheimer\u2019s disease: An in\u00a0vivo MRI and DTI study","volume":"32","author":"Teipel","year":"2011","journal-title":"Hum Brain Mapp"},{"key":"10.1016\/j.biopsych.2024.01.019_bib134","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000449011","article-title":"Pedunculopontine nucleus region deep brain\u00a0stimulation in\u00a0Parkinson disease: Surgical techniques, side effects, and postoperative imaging","volume":"94","author":"Hamani","year":"2016","journal-title":"Stereotact Funct Neurosurg"},{"key":"10.1016\/j.biopsych.2024.01.019_bib135","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","article-title":"Consensus nomenclature for in\u00a0vivo imaging of reversibly binding radioligands","volume":"27","author":"Innis","year":"2007","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2024.01.019_bib136","first-page":"166","article-title":"Probing cortical dopamine function in schizophrenia: What can D1 receptors tell us?","volume":"2","author":"Abi-Dargham","year":"2003","journal-title":"J\u00a0World Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib137","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1098-1063(1999)9:1<83::AID-HIPO9>3.0.CO;2-7","article-title":"Hippocampal system and declarative (relational) memory: Summarizing the data from functional neuroimaging studies","volume":"9","author":"Cohen","year":"1999","journal-title":"Hippocampus"},{"key":"10.1016\/j.biopsych.2024.01.019_bib138","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1037\/0894-4105.16.3.370","article-title":"Working memory for complex figures: An fMRI comparison of letter and fractal n-back tasks","volume":"16","author":"Ragland","year":"2002","journal-title":"Neuropsychology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib139","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1037\/h0040547","article-title":"Decision processes in perception","volume":"68","author":"Swets","year":"1961","journal-title":"Psychol Rev"},{"key":"10.1016\/j.biopsych.2024.01.019_bib140","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J\u00a0R Stat Soc B (Methodological)"},{"key":"10.1016\/j.biopsych.2024.01.019_bib141","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2024.01.019_bib142","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/cne.24541","article-title":"Regional vesicular acetylcholine transporter distribution in human brain: A [18 F]fluoroethoxybenzovesamicol positron emission tomography study","volume":"526","author":"Albin","year":"2018","journal-title":"J\u00a0Comp Neurol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib143","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","article-title":"Cognitive impairment in schizophrenia: Aetiology, pathophysiology, and treatment","volume":"28","author":"McCutcheon","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.01.019_bib145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10827-017-0666-4","article-title":"Disrupted cholinergic modulation can underlie abnormal gamma rhythms in schizophrenia and auditory hallucination","volume":"43","author":"Lee","year":"2017","journal-title":"J\u00a0Comput Neurosci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib146","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1038\/s41386-021-01070-x","article-title":"Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia","volume":"46","author":"Avram","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib147","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1523\/JNEUROSCI.22-09-03708.2002","article-title":"Prefrontal dopamine D1 receptors and working memory in schizophrenia","volume":"22","author":"Abi-Dargham","year":"2002","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib148","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/epi.14533","article-title":"Decreased vesicular acetylcholine transporter related to memory deficits in epilepsy: A [18 F] VAT positron emission tomography brain imaging study","volume":"59","author":"Wu","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.biopsych.2024.01.019_bib149","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.neuron.2011.03.014","article-title":"Neural systems governed by nicotinic acetylcholine receptors: Emerging hypotheses","volume":"70","author":"Miwa","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2024.01.019_bib150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1535-7597.2002.00072.x","article-title":"Neuronal nicotinic acetylcholine receptors and epilepsy","volume":"2","author":"Bertrand","year":"2002","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.biopsych.2024.01.019_bib151","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/npp.2010.104","article-title":"Modes and models of forebrain cholinergic neuromodulation of cognition","volume":"36","author":"Hasselmo","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib152","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1096\/fj.05-5497com","article-title":"Enhanced expression of hypersensitive alpha4\u2217 nAChR in adult mice increases the loss of midbrain dopaminergic neurons","volume":"20","author":"Schwarz","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.biopsych.2024.01.019_bib153","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0891-0618(00)00109-5","article-title":"The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia","volume":"20","author":"Freedman","year":"2000","journal-title":"J\u00a0Chem Neuroanat"},{"key":"10.1016\/j.biopsych.2024.01.019_bib154","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1176\/appi.ajp.2008.08050769","article-title":"Cholinergic agonists as novel treatments for schizophrenia: The promise of rational\u00a0drug development for psychiatry","volume":"165","author":"Lieberman","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2024.01.019_bib155","doi-asserted-by":"crossref","first-page":"33S","DOI":"10.2967\/jnumed.121.263198","article-title":"PET imaging of cholinergic neurotransmission in neurodegenerative disorders","volume":"63","author":"Tiepolt","year":"2022","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.biopsych.2024.01.019_bib156","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11307-007-0083-6","article-title":"Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders","volume":"9","author":"Bohnen","year":"2007","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.biopsych.2024.01.019_bib157","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/jnc.14291","article-title":"Kinetic modeling of [18 F]VAT, a novel radioligand for positron emission tomography imaging vesicular acetylcholine transporter in non-human primate brain","volume":"144","author":"Jin","year":"2018","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.biopsych.2024.01.019_bib158","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.2967\/jnumed.108.050716","article-title":"Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: A PET study with 2-18F-FA-85380","volume":"49","author":"Mukhin","year":"2008","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.biopsych.2024.01.019_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105152","article-title":"The impact of dopamine D2-like agonist\/antagonist on [18F]VAT PET measurement of VAChT in the brain of nonhuman primates","volume":"143","author":"Liu","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.biopsych.2024.01.019_bib160","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1021\/acs.molpharmaceut.1c00961","article-title":"No dopamine agonist modulation of brain [18F]FEOBV binding in Parkinson\u2019s disease","volume":"19","author":"Albin","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.biopsych.2024.01.019_bib161","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1038\/npp.2011.136","article-title":"Transient inactivation of\u00a0the\u00a0neonatal ventral hippocampus permanently disrupts the mesolimbic regulation of prefrontal cholinergic transmission: Implications for schizophrenia","volume":"36","author":"Brooks","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib162","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00213-008-1216-6","article-title":"A\u00a0neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia","volume":"202","author":"Sarter","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2024.01.019_bib163","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/npp.2009.105","article-title":"Disruption of\u00a0mesolimbic regulation of prefrontal cholinergic transmission in\u00a0an animal model of schizophrenia and normalization by chronic clozapine treatment","volume":"34","author":"Alexander","year":"2009","journal-title":"Neuropsychopharmacology"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322324000623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322324000623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:48:27Z","timestamp":1790297307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322324000623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":162,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0006322324000623"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2024.01.019","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging the Vesicular Acetylcholine Transporter in Schizophrenia: A Positron Emission Tomography Study Using [18F]-VAT","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2024.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}